SPOTLIGHT -
WHO HIV PrEP Recommendations Associated with Global Increase in Use
Global use of HIV pre-exposure prophylaxis has risen as more countries have adopted World Health Organization recommendations.
Read More
Johnson & Johnson HIV Vaccine Reports Low Efficacy in African Women Trial
New Imbokodo findings show a 4-dose regimen was only about 25% effective in preventing HIV in at-risk women, hindering progress for the vaccine.
HIV Combination Prevention Associated with Sharp Drop in Diagnoses
The adoption of numerous HIV prevention measures was associated with an 80% drop in the number of HIV diagnoses, a study evaluating the success of 56 Dean Street in London found.
The Potential Addition of Long-Acting Injectables for PrEP
What does this form of pre-exposure prophylaxis (PrEP) mean in terms of options and initiation.
Examining the HIV Treatment Pipeline
A review of selected investigational long-active treatment options for HIV.
Creating Greater PrEP Access with Large Public Health Goals and Local Service Models
Macro and micro strategies are at play in aiming to create greater PrEP access and adoption.
Approaching HIV Through Health Equity
A new study sought to approach the HIV epidemic in the United States through a distributional cost-effectiveness analysis across 6 cities.
The Future of HIV PrEP Is Individualized, Accessible
An expert from Temple reflects on the first 10 years of PrEP innovation, and what's needed in the next decade.
The Modern HIV PrEP Options and Care Teams Are Evolving
Pharmacist-initiated access, as well as longer treatment durations, may redefine HIV prevention efforts.
People with HIV and Low CD4 Could Experience Less Severe COVID-19
Reviewers attribute less severe COVID-19 symptoms in patients with HIV and low CD4 count to reduced capacity for immune reactions including cytokine storm.
Targeted HIV Screening Not Superior to Universal Testing in Emergency Departments
Three HIV screening strategies identified comparable numbers of new HIV diagnoses, a new study found.
Pharmacokinetics of Cabotegravir for HIV PrEP
Patients given a 600 mg injection of cabotegravir still had detectable levels of the drug in plasma, tissues, and fluids for 12 weeks.
PrEP Initiation is High Among Women in Africa, But Adherence Is Challenging
A recent study of sexually active young women in Africa found that initiation of HIV preexposure prophylaxis (PrEP) was high at 95% and one-fifth showed high adherence at 6 months.
CDC Releases Updated STI Treatment Guidelines
With millions of Americans affected by sexually transmitted infections (STI) an emphasis on prevention and control strategies was included in the recommendations.
Evaluating Adherence of PrEP Therapies
Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.
How Does Adherence of Daily Dosing vs Event-Driven PrEP Regimens Compare?
Adherence for daily dosing decreased and event-driven PrEP usage increased in a Chinese study.
Screening for Potential PrEP Users at Retail Pharmacies
In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.
Majority of PrEP Users Do Not Maintain Adherence
A meta-analysis study found that 70% of PrEP users either stopped or had inadequate adherence within 6 months of initiation.
The COVID-19 Pandemic and Resumption of PrEP Therapy
Small survey from gay and bisexual men (GBM) inquired about their experiences during COVID-19 restrictions, and feedback on PrEP.
Outreach for PrEP Counseling Shows Ability to Reach Underserved Communities
In Brazil, a concerted effort of recruiting adolescents was made to go out and talk with them about PrEP.
Mortality of People Entering HIV Care Drops, Nearing That of General Population
US residents with HIV have higher rates of mortality than their peers without infection, but the gap is narrowing, a recent study showed.
Understanding PrEP Preferences in a Select Population
Investigators surveyed men who have sex with men (MSM) about long-acting injectable pre-exposure prophylaxis (PrEP) including attitudes towards potentially taking it and barriers to usage.
HIV Testing, Positive Results Dropped in the US During COVID-19
The pandemic's effect on in-person care prioritization may have indirectly influenced the rate of screening opportunities in at-risk persons.
Cabotegravir Plus Rilpivirine Well-Received by HIV Care Staff, Patients at 12 Months
New findings from CUSTOMIZE suggest the once-monthly injection therapy was feasibly implemented and generally favored to once-daily tablets.
Study: Homeless Persons with HIV Prefer Flexible Care Models, No Telehealth
Perspective gained from persons treated a real-world clinic may help better inform strategies to treat an HIV population that often struggles with viral suppression and consistent care.
COVID-19 Severe Risks Not Significant in People with HIV
A new study from IAS 2021 suggests persons with HIV hospitalized for COVID-19 do not face worse mortality nor major cardiovascular event risk.
FDA Approves Expanded Indication for Secnidazole for Trichomoniasis
The therapy, developed by Lupin Pharmaceuticals, now includes the treatment of trichomoniasis in adults patients and their partners.
Long-Acting Antiretroviral Therapies for HIV Treatment and Prevention
More treatment options and modalities are now available for patients.
Public Health Watch: Latest STI Numbers for US a “Call to Action”
CDC report highlights disparities among “racial, ethnic, gender, and sexual” minorities.
NAFLD Is Increasingly Affecting Patients With HIV
The prevalence of this disease in this patient population is much higher than in the general public.